Secosteroid-2-Pyrazoline Hybrids: Design, Synthesis, Biological Evaluation and Development of Therapeutic...

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Cancer Biology

Background:

• Breast cancer is a leading global health concern, necessitating novel therapeutic strategies.
• Estrogen receptor-positive (ERα) breast cancer subtypes often rely on hormonal therapies.
• Developing new antitumor agents with improved efficacy and safety is crucial.

Purpose of the Study:

• To design and synthesize novel secosteroid-2-pyrazoline hybrids.
• To evaluate the antitumor activity of these hybrids against ERα-positive breast cancer cell lines (MCF-7 and T47D).
• To investigate the mechanism of action and safety profile of lead compounds.

Main Methods:

• Synthesis of secosteroid-2-pyrazoline hybrids from a secoestratriene hydrazide and 1,3-diketones.
• In vitro antiproliferative assays against MCF-7 and T47D breast cancer cells.
• Flow cytometry for cell-cycle analysis and Western blotting for signaling pathway investigation (S6K, Bcl-2, ERα).

Main Results:

• Compounds 3f, 3j, and 3k demonstrated potent antiproliferative activity (IC50: 0.2-0.5 μM) against breast cancer cells with low normal cell toxicity (IC50 > 25 μM).
• Lead compound 3j exhibited synergistic effects when combined with docetaxel and doxorubicin.
• The compounds inhibited S6 kinase and promoted Bcl-2 phosphorylation, inducing apoptosis and G1/G0 cell cycle arrest without affecting key hormonal targets.

Conclusions:

• Secosteroid-2-pyrazoline hybrids represent a promising class of novel anticancer agents for ERα-positive breast cancer.
• These compounds offer a dual mechanism targeting apoptosis and S6K signaling.
• The favorable safety profile suggests potential for next-generation breast cancer therapeutics.